Agenus (NASDAQ:AGEN) Downgraded to Hold Rating by Wall Street Zen

Wall Street Zen lowered shares of Agenus (NASDAQ:AGEN) from a buy rating to a hold rating in a report issued on Sunday.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Agenus in a report on Monday, December 29th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, Agenus currently has an average rating of “Hold” and an average target price of $14.50.

Agenus Stock Performance

Shares of NASDAQ:AGEN opened at $3.39 on Friday. The stock has a market capitalization of $130.18 million, a P/E ratio of -7.37 and a beta of 1.56. Agenus has a 1-year low of $1.38 and a 1-year high of $7.34. The business has a 50-day moving average price of $3.21 and a two-hundred day moving average price of $3.72.

Agenus (NASDAQ:AGEN) last released its earnings results on Monday, March 16th. The biotechnology company reported $0.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.27) by $1.83. Agenus had a negative net margin of 2.67% and a negative return on equity of 7.65%. The company had revenue of $34.20 million for the quarter, compared to the consensus estimate of $28.10 million. As a group, equities analysts predict that Agenus will post -12.55 EPS for the current year.

Institutional Trading of Agenus

Large investors have recently made changes to their positions in the company. Vanguard Group Inc. raised its stake in Agenus by 1.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,569,533 shares of the biotechnology company’s stock worth $9,893,000 after buying an additional 36,983 shares during the period. Renaissance Technologies LLC grew its stake in Agenus by 721.1% in the fourth quarter. Renaissance Technologies LLC now owns 543,546 shares of the biotechnology company’s stock valued at $1,707,000 after acquiring an additional 477,346 shares during the period. AQR Capital Management LLC increased its holdings in shares of Agenus by 3,080.3% in the first quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock worth $664,000 after acquiring an additional 427,604 shares in the last quarter. Marshall Wace LLP acquired a new stake in shares of Agenus during the second quarter worth about $1,976,000. Finally, Bank of America Corp DE raised its position in shares of Agenus by 110.0% during the second quarter. Bank of America Corp DE now owns 420,678 shares of the biotechnology company’s stock worth $1,922,000 after purchasing an additional 220,327 shares during the period. Institutional investors own 61.46% of the company’s stock.

Agenus Company Profile

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.